Aina Millán-Sánchez

Dr. Aina Millán-Sánchez

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2023 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Open access
NRNoèlia Loza Rodríguez
Noèlia Loza Rodríguez
AMAina Millán-Sánchez
Aina Millán-Sánchez
OLOlga Lopez
Olga Lopez
The development of biocompatible delivery systems is a necessity for medical and topical applications. Herein, the development of a new bigel for topical application is described. It is composed of 40% colloidal lipid hydrogel and 60% olive oil and beeswax oleogel. Its characterization and the potential of the bigel as a drug carrier through the skin was evaluated in vitro using fluorescence microscopy and two phases of the bigel were labeled with two fluorescent probes: sodium fluorescein (hydrophilic phase) and Nile red (lipophilic phase). The structure of the bigel showed two phases with fluorescence microscopy in which the hydrogel phase was incorporated into a continuous oleogel matrix. Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy (ATR-FTIR) presented a combination of vibrations characteristic of the different molecules forming the bigel, and Differential Scanning Calorimetry (DSC) showed different transitions attributed to beeswax lipids. Small-angle and wide-angle X-ray scattering (SAXS and WAXS) indicated a predominant lamellar structure with orthorhombic lateral packing that could be related to the arrangement of beeswax crystals. Bigel enables deeper penetration of hydrophilic and lipophilic probes into deeper layers, making it a promising candidate for effective topical carriers in medical and dermatological applications.

11 August 2023 in Gels
Verified
Journal Article
Open access
PDF file
NRNoèlia Loza Rodríguez
Noèlia Loza Rodríguez
AMAina Millán-Sánchez
Aina Millán-Sánchez
OLOlga Lopez
Olga Lopez
Ascorbic acid (AA) has many health benefits, including immune and cardiovascular deficiency protection, prenatal problems, and skin diseases. Unfortunately, AA is easily oxidized and has limited bioavailability. Thus, the development of formulations that stabilize and enhance the efficacy of AA is a challenge. In this study, 4% AA was encapsulated in two recently developed gels, a hydrogel and a bigel. The hydrogel was formed exclusively with lipids and water, and the bigel was a combination of the hydrogel with an oleogel formed with olive oil and beeswax. The effect of AA in gel microstructures was determined using X-ray scattering, rheology, and texture analysis. Additionally, the capacity of these materials to protect AA from degradation upon temperature and sunlight was studied. Results showed that the incorporation of AA into both materials did not affect their microstructure. Moreover, hydrogel-protected AA showed only 2% degradation after three months at 8 °C, while in aqueous solution, it degraded by 12%. Regarding sunlight, bigel showed a good shielding effect, exhibiting only 2% AA degradation after 22 h of exposure, whereas in aqueous solution, AA degraded by 10%. These results suggest that both proposed gels could be used in biomedical applications and the field of food.

7 September 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
NRNoèlia Loza Rodríguez
Noèlia Loza Rodríguez
AMAina Millán-Sánchez
Aina Millán-Sánchez
Mireia MallandrichMireia Mallandrich
Mireia Mallandrich
ANA CRISTINA CALPENAANA CRISTINA CALPENA
ANA CRISTINA CALPENA
OLOlga Lopez
Olga Lopez
This study explores the incorporation of 10% 3-O-ethyl L-ascorbic acid (ETVC), a derivative of vitamin C, into two lipid gel systems: a hydrogel (HG) consisting exclusively of lipids and water and a bigel (BG) combining the hydrogel with an oleogel made from olive oil and beeswax. We investigated the ETVC release profiles from both materials using synthetic membranes and measured their permeation through porcine skin in vitro. Additionally, the interaction of these lipid gel systems with the stratum corneum (SC) was determined. Results from the release study indicate that the BG exhibited slower ETVC release compared to the HG. The permeation experiments showed that the presence of lipids in the formulations enhanced ETVC retention in the skin. The HG delivered a higher amount to the SC, while the BG achieved greater retention in the epidermis. This difference is attributed to the different lipophilic nature of each material. The structural analysis of SC lipids revealed that the organization of surface lipids remained unaltered by the application of the gels. Finally, an in vitro efficacy test in porcine skin using methylene blue indicated that our ETVC gels exhibited antioxidant activity. These findings provide valuable insights into the potential of lipid-based gels for topical applications.

7 May 2025 in Materials Advances
Verified
Journal Article
Open access
PDF file
NRNoèlia Loza Rodríguez
Noèlia Loza Rodríguez
AMAina Millán-Sánchez
Aina Millán-Sánchez
ABAleix Benítez
Aleix Benítez
RPRamon Pons
Ramon Pons
MGMaría José Gómara
María José Gómara
OLOlga Lopez
Olga Lopez
A graphical representation of the development process of a lipidic hydrogel loaded with an anti-HIV peptide for pre-exposure prophylaxis: characterization, ex vivo mucosa permeation, and efficacy testing in vaginal mucosa.

13 December 2025 in JID Innovations
Verified
Journal Article
Open access
NPNuria Pell
Nuria Pell
PBPauline Bernard
Pauline Bernard
SCSéverine Courrech
Séverine Courrech
LOLukas Opalka
Lukas Opalka
AMAina Millán-Sánchez
Aina Millán-Sánchez
NJNathalie Jonca
Nathalie Jonca
Congenital ichthyoses, now renamed epidermal differentiation disorders (EDDs) (syndromic EDD or nonsyndromic EDD), are rare, disabling conditions caused by sequence variations in epidermal barrier genes. However, 5–10% of variants, called “variants of uncertain significance” (VUS), remain uncharacterized, and their pathogenicity is not demonstrated. We developed an approach for classifying VUS in nonsyndromic EDD associated with variant in PNPLA1. We generated PNPLA1-knockout human keratinocytes. PNPLA1, encoded by a missense VUS or by the reference coding sequence, was expressed after lentiviral transduction in the PNPLA1-knockout cells. Transduced cells were used to produce human epidermal equivalents, and the functionality of the normal or VUS-encoded proteins was evaluated. Compared with PNPLA1-knockout human epidermal equivalents re-expressing normal PNPLA1, PNPLA1-knockout human epidermal equivalents showed disrupted synthesis of ω-O-acylceramide, the normal product of PNPLA1, as well as abnormal vesicle-like structures and immature cornified envelopes, characteristic of the epidermis of patients with PNPLA1 variants. Human epidermal equivalents expressing the PNPLA1 VUS showed similar abnormalities, consistent with an impaired PNPLA1 function. This work demonstrated a feasible strategy to help reclassifying missense VUS, which can be extended to other EDD-related genes. Although further efforts are needed to translate this approach into clinical practice and help overcome current diagnostic limitations, such models are valuable tools for pathophysiological and preclinical research on EDDs.